By directly targeting several Wnt/β‐catenin antagonists including AXIN1, GSK3β and DKK1, miR‐31 promotes the Wnt signalling pathway and tumour development within mammary and small intestine.41, 49. Here, AXIN1 is linked to neoplasm.